Abeona Therapeutics Inc. (ABEO) P/E Ratio History
Historical price-to-earnings valuation from 2013 to 2025
Loading P/E history...
ABEO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Abeona Therapeutics Inc. (ABEO) trades at a price-to-earnings ratio of 5.7x, with a stock price of $5.77 and trailing twelve-month earnings per share of $1.08.
The current P/E is 42% above its 5-year average of 4.0x. Over the past five years, ABEO's P/E has ranged from a low of 0.5x to a high of 9.3x, placing the current valuation at the 83th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ABEO trades at a 74% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ABEO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABEO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABEO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 43.4 | -Best | +128%Best | |
| $4B | 9.9Lowest | -Best | +68% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ABEO Historical P/E Data (2013–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $5.27 | $1.01 | 5.2x | +29% |
| FY2025 Q3 | $5.28 | $1.14 | 4.6x | +15% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $5.68 | $0.61 | 9.3x | +132% |
| FY2013 Q4 | $312.50 | $103.82 | 3.0x | -25% | |
| FY2013 Q3 | Mon Sep 30 2013 00:00:00 GM | $562.50 | $1140.94 | 0.5x | -88% |
| FY2013 Q2 | Sun Jun 30 2013 00:00:00 GM | $600.00 | $397.69 | 1.5x | -62% |
Average P/E for displayed period: 4.0x
See ABEO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABEO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABEO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABEO — Frequently Asked Questions
Quick answers to the most common questions about buying ABEO stock.
Is ABEO stock overvalued or undervalued?
ABEO trades at 5.7x P/E, above its 5-year average of 4.0x. The 83th percentile ranking indicates a premium to historical valuation.
How does ABEO's valuation compare to peers?
Abeona Therapeutics Inc. P/E of 5.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ABEO's PEG ratio?
ABEO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2025.